Latest Content

What I Have Learned Helping Friends Through Health Scares

April 22nd 2021, 4:00pm

By Steve Rubin


Finding the balance between offering support and guidance while at the same time not overwhelming people going through health scares isn’t easy, writes a cancer survivor. He notes that although it may take some practice to get right, it is an important skill for cancer thrivers to get down.

A Cancer Research Writer Turns His Pain Into Hope For Others

April 22nd 2021, 3:00pm

By Jamie Cesanek


In this episode of the “CURE® Talks Cancer” podcast, Henry Scowcroft discusses his experiences writing a book about his late wife’s cancer journey and offers advice for other caregivers.

Keytruda Shows Promise for Certain Patients with Cutaneous Squamous Cell Carcinoma

April 22nd 2021, 1:00pm

By Colleen Moretti


Keytruda demonstrated clinical benefit for patients with recurrent and metastatic disease, according to an expert.

Targeting a Specific Genetic Mutation May Change Treatment Landscape for Non-Small Cell Lung Cancer

April 21st 2021, 9:00pm

By Darlene Dobkowski, MA


Patients with non-small cell lung cancer and a KRAS G12C genetic mutation may benefit from treatment with an inhibitor targeting that mutation, although more research is needed to learn why more patients are not responding to the drug.

Post-Traumatic Stress Disorder Prevalent in Patients with Acute Myeloid Leukemia

April 21st 2021, 6:00pm

By Colleen Moretti


Patients with acute myeloid leukemia experience post-traumatic stress disorder symptoms including intrusion, avoidance and hypervigilance one month after diagnosis.

When A Child is in Treatment for Cancer, Their Caregivers Become A Vital Resource

April 21st 2021, 4:00pm

By Eileen Weinmann


A pediatric oncology nurse offers advice for parents or primary caregivers on how to support their child during cancer treatment.

No Small Challenge: Emerging Therapies in Small Cell Lung Cancer

April 21st 2021, 3:00pm

By Erik Ness


In recent years, research in treating small cell lung cancer has broadened, bringing emerging therapies like immunotherapy to the forefront.

How the Evolving Pancreatic Cancer Treatment Landscape Has Improved Patient Outcomes

April 21st 2021, 1:00pm

By Jessica Skarzynski


Though the two major modalities of surgery and chemotherapy have been constants in pancreatic cancer treatment for many years, patient outcomes have gradually improved over time as doctors have refined their approach, says an expert from the Seattle Cancer Care Alliance.

Active Surveillance Occurs Frequently Versus Systemic Therapy for Metastatic Renal Cell Carcinoma

April 20th 2021, 9:00pm

By Darlene Dobkowski, MA


Certain patients with metastatic renal cell carcinoma may benefit with active surveillance compared with systemic therapy for their management and may also lead to an improved quality of life.

Cell-Based Therapies May ‘Level the Playing Field’ in Non-Small Cell Lung Cancer

April 20th 2021, 6:00pm

By Meeri Kim


Even with all the recent advances in targeted therapies and immunotherapy drugs, patients with non-small cell lung cancer still need more treatment options. Although it’s early, cell-based therapies have shown some promise, with more research underway.

Experiencing a Double Whammy: Chemo and COVID-19 Fog

April 20th 2021, 4:00pm

By Jane Biehl Ph.D.


A cancer survivor describes what “chemo fog” is and writes how many people are now experiencing a double whammy — “pandemic fog.”

Real Burden of Cancer ‘Won’t Go Away’ Because of COVID-19

April 20th 2021, 3:00pm

By Jamie Cesanek


After the COVID-19 pandemic caused a delay in cancer screenings, an expert from Karmanos Cancer Hospital and Network urges patients to resume their routine preventative care to avoid any delay in a possible diagnosis.

Delayed Surgery Possible With Surveillance in Patients With Sentinel Lymph Node Positive Melanoma

April 20th 2021, 1:00pm

By Colleen Moretti


Active surveillance in sentinel lymph node positive melanoma could delay surgery but may result in the same risk of the cancer coming back.

Keytruda Improves Progression-Free Survival in Subset of Patients With Relapsed/Refractory Hodgkin Lymphoma

April 19th 2021, 9:00pm

By Darlene Dobkowski, MA


Median progression-free survival in patients treated with Keytruda was 13.2 months versus 8.3 months with Adcetris, which makes Keytruda an “effective treatment option” for patients in this population who were either ineligible for or relapsed after autologous hematopoietic stem cell transplantation.

Cancer Survivors and Patients Share Their Experience With Seeking Second Opinions on Their Diagnosis and Treatment

April 19th 2021, 6:00pm

By Ryan McDonald


On social media, CURE® recently asked its readers to share if they sought a second opinion when discussing their cancer diagnosis and treatment. Here’s what some of them said.